PM
CUE icon

Prosight Management’s Cue Biopharma CUE Stock Holding History

Prosight Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-38,395
Closed -$4.11M – 40
2023
Q1 		$4.11M Sell
38,395
-22,955
-37% -$2.19M 1.95% 20
2022
Q4 		$5.25M Buy
61,350
+9,831
+19% +$899K 2.86% 13
2022
Q3 		$3.45M Sell
51,519
-3,664
-7% -$315K 1.85% 16
2022
Q2 		$4.12M Buy
55,183
+4,840
+10% +$566K 3.25% 12
2022
Q1 		$7.37M Buy
50,343
+22,708
+82% +$4.82M 4.76% 7
2021
Q4 		$9.38M Buy
27,635
+5,795
+27% +$2.24M 5.61% 5
2021
Q3 		$9.55M Buy
21,840
+828
+4% +$289K 5.25% 4
2021
Q2 		$7.34M Buy
21,012
+2,453
+13% +$951K 4.59% 5
2021
Q1 		$6.79M Sell
18,559
-11,660
-39% -$4.8M 5.56% 5
2020
Q4 		$11.3M Buy
30,219
+6,554
+28% +$2.62M 5.24% 4
2020
Q3 		$10.7M Buy
23,665
+13,322
+129% +$7.68M 5.08% 5
2020
Q2 		$7.61M Sell
10,343
-8,059
-44% -$5.84M 3.26% 10
2020
Q1 		$7.83M Buy
18,402
+13,814
+301% +$6.7M 3.66% 10
2019
Q4 		$2.19M Buy
+4,588
New +$1.44M 0.96% 29

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Prosight Management's CUE Position: Q2 2023 in Review

Prosight Management sold out of Cue Biopharma (CUE) in Q2 2023, closing a stake of 38,395 shares — an estimated $4.11M sold.

Prosight Management first reported a position in CUE in Q4 2019 and held it in 14 quarters. The position peaked at $11.3M in Q4 2020. 78 funds tracked by Wall St. Rank hold CUE as of Q2 2023.

  • Prosight Management reported no remaining Cue Biopharma position as of Q2 2023 after selling out during the quarter.
  • Prosight Management sold 38,395 Cue Biopharma shares in Q2 2023, an estimated $4.11M.
  • Prosight Management first reported a position in Cue Biopharma in Q4 2019 and held it in 14 quarters.
  • Prosight Management's Cue Biopharma position peaked at $11.3M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2023.

Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.